ClinicalTrials.gg
RecruitingNCT06164795STARTUpdated Jul 22, 2026

Sequential Therapies After Osteoanabolic Treatment

An observational study in Osteoporosis, Postmenopausal, sponsored by 424 General Military Hospital. Recruiting at 8 sites in 2 countries. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by 424 General Military Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
50 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Osteoporosis, Postmenopausal with a site in Greece — 2 open to participants now, 3 under way, none of them phase 3. Osteoporosis, Postmenopausal · Greece.

Started
2023
with 1 other
Observational
7 of 14
2 open now
Registered
13th of 14
by date
Lead sponsor
4 of 14
424 General Military Hospital

Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 13th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

2 of the 14 studies in Osteoporosis, Postmenopausal with a site in Greece are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Osteoporosis, Postmenopausal with a site in Greece, or all of them as a file.
02

Study summary

12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics

Read the detailed description

Caucasian women with severe postmenopausal osteoporosis who have completed their course with romosozumab or a PTH analog will be assigned to one of the following 3 options: i) zoledronate 5mg infusion or ii) denosumab subcutaneous injections or iii) teriparatide or abaloparatide (for those previously treated with romosozumab) or romosozumab (for those previously treated with teriparatide or abaloparatide).

Endpoints: Primary: BMD changes at the lumbar spine at 12 months. Secondary: i) BMD changes at the non-dominant femoral neck and total hip at 12 and 24 months; ii) changes at levels of bone turnover markers throughout the study; iii) incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Postmenopausal women treated with severe osteoporosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women treated with severe osteoporosis completing their course with romosozumab or teriparatide

Exclusion criteria

Exclusion Criteria:

  • a bone disease other than osteoporosis
  • use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study
  • \<60 mL/min/1.73 m2
  • liver failure
  • any type of cancer
  • uncontrolled endocrine diseases
  • serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L)
  • to denosumab or zoledronate or teriparatide or romosozumab or any of the
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Romo-Zol group

    Postmenopausal women treated with romosozumab for 12 months will receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose

    Drug: Zoledronate

  • Romo-Dmab group

    Postmenopausal women treated with romosozumab for 12 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months starting at 1 month after the last romosozumab dose

    Drug: Denosumab

  • Romo-PTH group

    Postmenopausal women treated with romosozumab for 12 months will receive daily injections of teriparatide 20μg or abaloparatide 80μg for 12 months starting at 1 month after the last romosozumab dose

    Drug: Teriparatide · Drug: Abaloparatide Injection (80 mcg)

  • PTH-Zol group

    Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 monthswill receive a single zoledronate infusion (5mg) at 1 month after the last romosozumab dose

    Drug: Zoledronate

  • PTH-Dmab group

    Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 months will receive subcutaneous denosumab injections (60mg) bi-annually for 12 months

    Drug: Denosumab

  • TPTD-Romo group

    Postmenopausal women treated with teriparatide for 24 months or abaloparatide for 18 months will receive month injections of romosozumab for 12 months

    Drug: Romosozumab

Interventions

06

What researchers measure

Primary outcomes

  1. lumbar spine bone mineral density

    bone mineral density changes at the lumbar spine at 12 months measured by dual-energy absorptiometry (DXA)

    Time frame: baseline to 12 months

Secondary outcomes

  1. femoral neck bone mineral density

    bone mineral density changes at the femoral neck at 12 months measured by dual-energy absorptiometry (DXA)

    Time frame: baseline to 12 months

  2. total hip bone mineral density

    bone mineral density changes at the total hip at 12 months measured by dual-energy absorptiometry (DXA)

    Time frame: baseline to 12 months

  3. P1NP

    bone turnover (formation) marker

    Time frame: baseline, 3 months, 6 months, 12 months

  4. CTx

    bone turnover (resorption) marker

    Time frame: baseline, 3 months, 6 months, 12 months

  5. Fractures

    incident fractures: vertebral (clinical and morphometric identified on VFA scans) and non-vertebral

    Time frame: 12 months

07

Study locations

8 of 8 sites recruiting
  • 251 Airforce & VA General Hospital
    Athens, 11525, Greece
    Recruiting
  • First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens
    Athens, 11527, Greece
    Recruiting
  • , KAT General Hospital
    Athens, 14561, Greece
    Recruiting
  • 424 General Military Hospital
    Thessaloniki, 56429, Greece
    Recruiting
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
    Milan, Italy
    Recruiting
  • Campus Bio-Medico University
    Roma, 00128, Italy
    Recruiting
    • Andrea Palermo, Ass Prof · ContactA.Palermo@unicampus.it
    • Gaia Tabacco, PhD · Contact
    • Anda Naciu, PhD · Sub investigator
    • Gaia Tabacco, PhD · Sub investigator
  • Department of Medicine, Surgery and Neurosciences, University of Siena
    Siena, 53100, Italy
    Recruiting
    • Luigi Gennari, prof · Contactgennari@unisi.it
    • Daniela Merlotti · Contact
    • Daniela Merlotti · Sub investigator
  • University-Hospital S. Maria della Misericordia
    Udine, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.

Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 11, 2023
StartActual
Nov 25, 2023
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06164795
Lead sponsor
424 General Military Hospital
Collaborators
Laikο General Hospital, Athens, 251 Hellenic Air Force & VA General Hospital, KAT General Hospital, Campus Bio-Medico University, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano, Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, University of Siena
Responsible party
Athanasios D. Anastasilakis (Head of the Department of Endocrinology, 424 General Military Hospital) — Principal investigator
First posted
Dec 11, 2023
Start date
Nov 25, 2023
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Athanasios D Anastasilakis, PhD
Contact
a.anastasilakis@gmail.com
2310381431 ext. +30
John Carey, Prof
Contact
john.j.carey@universityofgalway.ie
Willem Lems, Prof
study chair · ECTS Clinical Action Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion